Atypical and typical neuroleptics in acute schizophrenia and related delusional disorders: Drug choice, switching and outcome under naturalistic treatment conditions

European Archives of Psychiatry and Clinical Neuroscience

Volumn 253, Issue 4, 2003, Pages 175-184

  Gaebel, Wolfgang ^a   Riesbeck, Mathias ^a   Janssen, Birgit ^a   Schneider, Frank ^a   Held, Tilo ^b   Mecklenburg, Hermann ^c   Saß, Henning ^d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Fliedner Klinik   (Germany)

^c Institute of Pathology   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Acute drug treatment; Drug switching; Schizophrenia; Treatment guidelines; Typical and atypical neuroleptics

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROTHIXENE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PROMETHAZINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; ZOTEPINE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DELUSIONAL DISORDER; DISEASE DURATION; DRUG CHOICE; DRUG EFFICACY; FEMALE; GERMANY; HOSPITAL PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL INTERACTION; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0141790906     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-003-0422-9     Document Type: Article

References (35)

1. American Psychiatric Association (APA) (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). APA, Washington DC
2. American Psychiatric Association (1997) Practice guidelines for the treatment of patients with schizophrenia. Washington, DC
3. Brunot A, Lachaux B, Sontag H, Casadebaig F, Philippe A, Rouil-Ion F, Clery-Melin P, Hergueta T, Llorca PM, Moreaudefarges T, Guillon P, Lebrun T (2002) Etude pharmaco-epidemiologique de la prescription des antipsychotiques en milieu psychiatrique en France. Encephale 28(2):129-138
4. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 158:518-526
5. CIPS (1981) Collegium Internationale Psychiatriae Scalarum (eds) Internationale Skalen für Psychiatrie. Berlin
6. Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002) Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28(1):75-84
7. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (1998) Praxisleitlinien in Psychiatrie und Psychotherapie. Red.: Gaebel W, Falkai P (eds) Band 1: Behandlungsleitlinien Schizophrenie. Steinkopff Verlag, Darmstadt
8. Frangou S, Lewis M (2000) Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. Eur Psychiatry 15(3):220-226
9. Gaebel W, Schneider F, Janssen B (2000) Qualitätsoptimierung klinischer Schizophreniebehandlung. Steinkopff, Darmstadt
10. Galvin PM, Knezek LD, Rusch AJ, Toprac MG, Johnson B (1999) Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Clin Ther 21(6):1105-1116
11. Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371-1376
12. Janssen B, Burgmann C, Habel U, Held T, Hoff P, Janner M, Mecklenburg H, Pruter C, Ruth A, Sass H, Schneider F, Gaebel W (2000) External quality assurance of inpatient treatment in schizophrenia. Results of a multicenter study. Nervenarzt 71:364-372
13. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
14. Kapur S, Remington G (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Ann Rev Med 52:503-517
15. Kasper S, Hale A, Azorin JM, Möller HJ (1999) Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 249 (Suppl. 2):111-1114
16. Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, Weiden P (1993) Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 29:309-314
17. Knapp M (2000) Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatr Scand 102(407):Suppl 15-18
18. Lehman AF, Steinwachs DM (1998) Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 24:1-10
19. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51-68
20. Martin BC, Miller LS, Kotzan JA (2001) Antipsychotic prescription use and costs for persons with schizophrenia in 1990s: current trends and five year time series forecasts. Schizophr Res 47:281-292
21. McEvoy JP, Scheifler PL, Frances A (1999) The expert consensus guideline series. Treatment of schizophrenia. J Clin Psychiatry 60:1-80
22. Moller HJ (1996) Review: treatment of schizophrenia. State of the art. Eur Arch Psychiatry Clin Neurosci 246:229-234
23. National Institute for Clinical Excellence (NICE) (2002) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Guidance No. 43. www.nice.org.uk
24. Revicki DA (1999) Pharmacoeconomic studies of typical antipsychotic drugs for the treatment of schizophrenia. Schizophrenia Research 35(Suppl.):101-109
25. Schwabe U, Pfaffrath D (eds) (2003) Arzneimittelverordnungsreport 2002. Springer, Berlin/Heidelberg/New York
26. Spiessl H, Cording C, Klein HE (1995) Erfassung der Patientenzufriedenheit in der Psychiatrie. Krankenhauspsychiatrie 6:156-159
27. Steel RM, Johnstone EC (2000) Should the treatment of schizophrenia include old antipsychotic drugs? Curr Psychiatry Rep 2:404-409
28. Strauss JS, Klormann R, Kokes RF (1977) Premorbid adjustment in schizophrenia: concepts, measures, and implications. Part V. The implications of findings for understanding, research, and application. Schizophr Bull 3:240-244
29. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N (2003) Combination antipsychotic therapy in clinical practice. Psychiatric services 54(1):55-59
30. Tilden D, Aristides M, Meddis D, Burns T (2002) An economic assessment of quietapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. Clin Ther 24(10):1648-1667
31. Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK (1999) Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry 60(Suppl. 19):38-45 (discussion 46)
32. Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, Awad A (2002) Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 57:201-208
33. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A (2000) Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 43:135-145
34. World Health Organization (1978) Mental disorders: glossary and guide to their classification in accordance with the Ninth Revision of the International Classification of Diseases. WHO, Geneva
35. World Psychiatric Association (2000) Consensus statement on usefulness and use of second generation antipsychotic medications. Unpublished manuscript